Uggowitzer M, Kugler C, Gröll R, Mischinger H J, Stacher R, Fickert P, Weiglein A
Department of Radiology, University of Graz, Austria.
Br J Radiol. 1998 Oct;71(850):1026-32. doi: 10.1259/bjr.71.850.10211062.
Focal nodular hyperplasias (FNH) are hypervascular, benign focal liver lesions. Differentiation of FNH from other focal liver lesions is of clinical importance. The purpose of this study was to examine the impact of a new, transpulmonary echo-enhancing agent SHU 508A (Levovist) and recent Doppler techniques in the sonographic evaluation of FNH. 43 patients with 61 focal nodular hyperplasias of the liver were examined with grey scale ultrasound and power Doppler ultrasound. Levovist, a galactose-air-microbubble suspension was administered intravenously in all patients, either by bolus injection (400 mg ml-1) or continuous pump-infusion (300 mg ml-1). Visualization of the feeding vessels and vascularity of the lesions were evaluated. The resistance indexes (RI) in the feeding vessel and the hepatic artery were assessed and compared with the diameters of the FNH. The mean diameter of FNH was 4.3 cm (+/- 1.0). Echo enhanced power Doppler ultrasound was superior to unenhanced power Doppler ultrasound in the detection of the feeding artery (85% vs. 98%) in FNH and depicted the internal vascular architecture more clearly, especially in lesions located in the left lobe of the liver. Lesions smaller than 3 cm did not show a characteristic vascular architecture with echo enhanced Doppler ultrasound. The resistance index of the feeding artery (mean: 0.51 +/- 0.08) is significantly (p < 0.0001) lower than that of the hepatic artery (mean 0.65 +/- 0.06) with a mean difference of -0.14 +/- 0.01 in the same patient. The RI of the feeding artery significantly decreased as the size of the FNH increased, whereas RI differences between the hepatic artery and the feeding artery increased with lesion size. Intravenous (i.v.) bolus injection of the contrast agent will depict the hypervascular nature of FNH more clearly than i.v. infusion, although the latter will significantly prolong the diagnostic window. In conclusion, i.v. infusion of Levovist improves the visualization of the feeding artery and the radiating vascular architecture in FNH located in the left lobe of the liver due to improved signal-to-noise ratio and results in more effective suppression of motion artefacts. Although echo enhanced Doppler ultrasound improves the detection of the low resistance arterial feeding vessel in small FNH, it will not, however, reveal a specific vascular pattern in these lesions.
局灶性结节性增生(FNH)是肝脏的高血供良性局灶性病变。鉴别FNH与其他肝脏局灶性病变具有重要临床意义。本研究旨在探讨新型经肺超声造影剂SHU 508A(Levovist)及近期多普勒技术在FNH超声评估中的作用。对43例患有61个肝脏局灶性结节性增生的患者进行了灰阶超声和能量多普勒超声检查。所有患者均静脉注射Levovist,一种半乳糖-空气微泡混悬液,采用团注(400mg/ml)或持续泵注(300mg/ml)。评估病变供血血管的显示情况及病变的血管分布。测定并比较供血血管和肝动脉的阻力指数(RI)与FNH的直径。FNH的平均直径为4.3cm(±1.0)。在FNH中,超声造影增强能量多普勒超声在显示供血动脉方面优于未增强的能量多普勒超声(85%对98%),且能更清晰地显示内部血管结构,尤其是位于肝左叶的病变。小于3cm的病变在超声造影增强多普勒超声下未显示出特征性血管结构。同一患者中,供血动脉的阻力指数(平均:0.51±0.08)显著低于肝动脉(平均0.65±0.06),平均差值为-0.14±0.01。随着FNH大小增加,供血动脉的RI显著降低,而肝动脉与供血动脉之间的RI差值随病变大小增加。静脉团注造影剂比静脉输注更能清晰显示FNH的高血供特性,尽管后者会显著延长诊断窗。总之,静脉输注Levovist可提高肝左叶FNH供血动脉及放射状血管结构的显示,这是由于信噪比提高且能更有效地抑制运动伪像。尽管超声造影增强多普勒超声可提高小FNH中低阻力动脉供血血管的检出率,但在这些病变中不会显示出特定的血管模式。